Login / Signup
No additive effects of peginterferon on the short-term improvement of liver histology by entecavir monotherapy in chronic hepatitis B patients.
Tatsuo Kanda
Published in:
Hepatology international (2021)
Keyphrases
</>
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
hepatitis b virus
peritoneal dialysis
randomized controlled trial
clinical trial
combination therapy
open label
patient reported outcomes